Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

December 01, 2021 03:12pm

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

Resistant Kawasaki Disease Treatment Efficacy
Results of INSTRIDE Studies for Diabetes Management
Role of Interchangeable Biosimilars in the Management of Diabetes
Basal Insulin Therapies for Diabetes Management